|
#1
|
|||
|
|||
|
The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.
More... |
![]() |
| Thread Tools | Search this Thread |
| Display Modes | |
|
|